An interventional study of Aerosol Box (Splashguard) in Coronavirus, Covid19 and COVID-19 Acute Respiratory Distress Syndrome, sponsored by KidSIM Simulation Program. Completed at 4 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-01.
Sponsored by KidSIM Simulation Program · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 289 studies in COVID-19 with a site in Canada — 24 open to participants now, 36 under way, 8 of them phase 3. COVID-19 · Canada.
Among the 289 studies in COVID-19 with a site in Canada, this one is the 96th largest by enrollment of the 200 interventional ones that give a count, is one of 95 that started in 2021, is one of 90 with no phase, and was the 175th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →24 of the 289 studies in COVID-19 with a site in Canada are open now. Recruiting first, the newest first:
University of British Columbia · Sites in Canada
Healthy volunteers
ParagonClinicals Inc. · Sites in Canada
Ages 19+
Unity Health Toronto · Sites in Canada
Ages 18+
Douglas D. Fraser · Sites in Canada, United States, Brazil and 4 more countries
Ages 18–65
McMaster University · Sites in Canada
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
289 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 51 · Phase 3 55 · Phase 4 6
First in 2014; this study’s year is marked. 95 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 122 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 120 across the 200 interventional studies, 355 across the 88 observational. Of the 196 that completed or were terminated, 36 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 289 have an industry lead sponsor. The 10 most frequent:
KidSIM Simulation Program is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
KidSIM Simulation Program has 2 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
12 of the studies in COVID-19 with a site in Canada that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07314905Phase 3Unity Health TorontoAdaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp) | 2027-03-31 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
Add all 12 to your calendar (.ics) → With an account.
Among the 289 studies in COVID-19 with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Aerosol Generating Medical Procedures (AGMP) are procedures that have the potential to create tiny particles suspended in the air. These particles can contain germs such as viruses. The current Coronavirus Disease 2019 (COVID-19) pandemic is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients infected with SARS-CoV-2 experience unusually high rates of critical illness that needs advanced airway management and intensive care unit admission. Bag-valve-mask (BVM) ventilation, laryngeal mask airway insertion (LMA), and endotracheal Intubation (ETI) are common AGMP for critically ill COVID-19 patients, and may contribute to a high risk of infection amongst Health Care Workers (HCW). To lessen HCW risk during high-risk AGMPs, a device called an aerosol box has been developed to place over the head of the patient, shielding the provider's face from virus droplets suspended in the air.
The purpose of this research study is to better understand how particles disperse during AGMPs. The project team hopes what is learned from the project can help inform infection control measures. This could help make changes to the clinical environment and make it safer for HCW's. The investigators intend to investigate how an aerosol box performs in reducing contamination of HCW's who perform critical airway interventions.
The investigators plan to conduct a prospective, randomized controlled trial at four INSPIRE network sites (Alberta Children's Hospital, Ste. Justine Hospital, and Children's Hospital of Los Angeles and The Hospital for Sick Children). Simulation-based research confers the advantage of answering research questions without risk of harm to HCPs or patients, which is particularly important when studying a disease process with high mortality. Ethics approval has been submitted at all sites. Two participants will form an airway team, recruited to play the roles of airway provider and airway assistant for management of a simulated, critically ill COVID-19 patient. Participants will be randomized by team into either the control arm (i.e. no aerosol box) or the intervention arm (i.e. use of aerosol box). Following randomization, all participants will view a short video orienting them to the simulated clinical environment. Intervention arm teams will view an additional 5-minute video orienting them to the use of the aerosol box, and receive up to 15 minutes of hands-on training (see below for details). After orientation, teams will participate in three sequential simulation scenarios. The order of scenario delivery will be randomized to eliminate scenario order as a potential confounder. The location and nature of equipment, temperature and humidity within the resuscitation room will be standardized across all sites. A Laerdal Resusci-Anne manikin will be used as a simulated patient.
The aerosol box is a transparent, plastic cube covering the patient's head and shoulders, with circular access ports on the front of the box allowing for access to manage the airway. An additional four access holes (i.e. two on either side of the box) allow for airway assistants to access the patient airway. As our study includes only one airway assistant, the two holes that are not in use will be sealed shut during the study. The airway assistant will be directed to stand in a standardized position, to the immediate right of the airway provider. In a prior study, an aerosol box placed over the head of an adult volunteer demonstrated air leaks out of the box during exhalation and coughing that could be eliminated with the addition of a plastic drape. For this reason, the investigators have incorporated a plastic drape extending from the top of the box down to the patient's chest to prevent spread of aerosols. In another experiment, the addition of continuous wall suction to the aerosol box setup resulted in significantly decreased airborne particle exposure (for the airway provider) compared to aerosol box use without suction. Given that wall suction is ready available and accessible in most acute care areas, the aerosol box setup will include wall suction, with suction tubing running into the aerosol box at one point along the bottom of the box near the head of the patient. Wall suction will be set at 200 mmHg, which is consistent with the pressure used in prior studies to generate a negative airflow of approximately 50 L/min.
All participants (i.e. airway provider and airway assistant) randomized to the intervention arm will receive aerosol box training. A 5-minute video will orient participants to the design of the aerosol box and include expert-modeled demonstration of strategies for optimal BVM ventilation, ETI, and LMA insertion using an aerosol box with a 2-person airway team. The training video will be shot in English and French to permit viewing across study sites in Alberta, Ontario and Quebec. After viewing the video, participants will work in pairs to practice all three procedures for a maximum of 15 minutes, providing them opportunity to coordinate their movements to optimize efficiency. After each procedure, the participants will receive feedback from a local airway and aerosol box expert (i.e. site investigator).
The amount of aersolization that occurs in real patients is highly variable and dependent upon many factors (e.g. viral load, method of aerosolization, etc.), making it impossible to exactly replicate aerosolization of SARS-CoV-2 virus in the simulated environment. In this study, the investigators aim to create a model of aerosolization by standardizing various aspects of care (e.g. ventilation pressures, particle size and volume deposited, lung compliance), thus allowing us to make comparisons between different contexts (ie. aerosol box vs no box; BVM vs. LMA vs. ETI). To visualize aerosolization of particles, the study team will adapt methodology successfully utilized in studies evaluating aerosolization during airway management. GloGerm©™(Glo Germ Company, Moab, UT, USA) is a nontoxic, invisible fluorescent resin marker that illuminates when exposed to ultraviolet (UV) light. The SARS-CoV-2 virus requires a water and mucus envelope to spread, with the size of these virus-containing envelopes varying from larger droplets (>60 µm) to smaller airborne particles or infectious droplet nuclei (5-10 µm diameter). With a particle size of approximately 5 µm, Glo Germ™ represents a reasonable surrogate for aerosolized SARS-CoV-2. AGMPs can generate aerosols in two ways: by mechanically inducing and dispersing aerosols, or by inducing the patient to cough to produce aerosols. This study focuses on aerosols mechanically induced by three commonly performed AGMPs: BVM ventilation, LMA insertion, and ETI. Glo Germ™(0.5 mL) will be applied to the oropharynx and trachea of the manikin to simulate secretions. Glo Germ™ will be aerosolized from the mechanical pressures and airflow associated with bagging, or from manipulation of the airway, which is consistent with the current understanding of aerosolization mechanics in AGMPs. Participants will titrate ventilation pressures to 20 cm H2O peak inspiratory pressure, and 5-6 cm H2O peak end expiratory pressure using a digital pressure manometer that provides real-time feedback. Pilot work done using the methods (and ventilation pressures) described above resulted in contamination on the hands, torso, face shield, and feet of airway providers during BVM ventilation. This suggests these methods are sufficient to produce a measurable amount of Glo Germ™ particles during manual ventilation.
Prior to each scenario, all participants will donn personal protective equipment (PPE), consisting of: a gown, nitrile gloves, face shield, googles, and a N95 respirator. The brand, type and size of gowns and face shields will be standardized across all sites. PPE will be donned with a partner, guided by a standardized PPE donning checklist, and checked by a research assistant prior to the scenarios. All scenarios are 5 minutes in duration and tightly standardized by using a scenario template with pre-scripted patient progression. Intervention arm teams will use the aerosol box in all three scenarios while control arm teams will not use the aerosol box. At the end of the entire session, participants will receive an educational debriefing to discuss performance issues, infection control measures, and technical skills using a blended-method approach to debriefing. Doffing will occur in conjunction with a PPE partner, and guided by a standardized PPE doffing checklist to ensure consistency.
Scenario A: BVM Ventilation - depicts an adolescent patient with suspected COVID-19, presenting with progressive respiratory distress and desaturation. Participants will be directed to initiate BVM ventilation with a HEPA filter as per guidelines for managing COVID-19 pediatric patients. Aerosolization of particles occurs during manual ventilation, while the mask is on the patient's face. The scenario will last a total of 5 minutes.
Scenario B: ETI - depicts an adult patient with suspected COVID-19, presenting with progressive respiratory failure requiring intubation. In this scenario, providers will be advised by the team leader not to initiate BVM ventilation, which is consistent with AHA guidelines for adult COVID-19 patients requiring airway management. Participants will be directed to sedate, paralyze and intubate the patient using a videolaryngoscope (e.g. GlideScopeTM), and provide manual ventilation after intubation with a HEPA filter in place. The scenario will last a maximum of 5 minutes, or until the patient is successfully intubated, whichever is longer.
Scenario C: LMA Insertion - depicts the same patient as in Scenario B. In this scenario, providers will be advised by the team leader to insert an LMA. Participants will be directed to sedate, paralyze and intubate the patient, and provide manual ventilation after LMA insertion with a HEPA filter in place. The scenario will last a maximum of 5 minutes, or until the patient is successfully intubated, whichever is longer.
Data collection will occur immediately after each scenario, prior to and after doffing of PPE (see outcomes below). After data collection, the resuscitation room and airway trainer will be cleaned. Clean PPE will be provided for all participants for each scenario. These measures will ensure there is no incremental accumulation of GloGermTM particles from prior scenarios. All scenarios will be videotaped from a birds-eye view angle at the head of the bed. Video from the video laryngoscopy device will be captured during Scenario B.
Randomization will occur at the level of the team, stratified by study site and sex of the airway provider (to ensure equal distribution of sex in both arms), and conducted in blocks of 4 to ensure an even distribution of teams across study arms. Randomization packages will be prepared at a central study side using a web-based random number generator. Sequentially numbered recruitment packages provided for each site will contain sealed opaque envelopes (i.e. one envelope per study arm) with study arm assignments and unique identifier codes for participants.
Sample size estimation is based on primary outcome measure. Given the paucity of quantitative research in this area, the investigators propose a sample of 60 teams (120 participants) in total, or 30 teams (60 participants) per study arm. As each team will receive repeated measures (i.e. 3 scenarios), this sample size permits detection of a medium effect size (Cohen's d = 0.65), with a significance level of 0.05, a power of 0.8, and a high intra-cluster correlation coefficient (rho = 0.7) to make a conservative estimation. Accounting for missing data due to technical issues, the investigators will recruit one extra team per study group at each site. Therefore, the total sample size will be 66 teams (132 participants).
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
This study's enrollment of 122 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Browse COVID-19 studies →KidSIM Simulation Program is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria (Airway Provider):
Inclusion Criteria (Airway Assistant)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will perform the AGMP without an aerosol box
Participants will perform the AGMP with an aerosol box
Device: Aerosol Box (Splashguard)
The aerosol box is a transparent, plastic cube covering the patient's head and shoulders, with circular access ports on the front of the box allowing for access to manage the airway. An additional four access holes (i.e. two on either side of the box) allow for airway assistants to access the patient airway.
Change in Integrated Density (Pre vs Post Doffing)
Integrated density of HCP contamination, quantified from digital photos of GloGerm™ deposited on the airway team members pre and post-doffing.
Time frame: Immediately after each procedure (BVM, ETI, LMA)
Change in Area of contamination (Pre vs Post Doffing)
Quantified from digital photos of GloGerm™ deposited on the airway team members pre and post-doffing.
Time frame: Immediately after each procedure (BVM, ETI, LMA)
Time to task completion
time to successful intubation or LMA insertion (captured by video review by 2 trained and calibrated raters)
Time frame: Immediately after ETI and LMA procedures
First pass success rate
first pass success rate for ETI and LMA insertion (captured by video review by 2 trained and calibrated raters)
Time frame: Immediately after ETI and LMA procedures
Number of healthcare providers contaminated
Number of healthcare providers contaminated
Time frame: Immediately after each procedure (BVM, ETI, LMA)
Number of different body parts contaminated
Number of different body parts contaminated
Time frame: Immediately after each procedure (BVM, ETI, LMA)
Environmental Contamination
integrated density of environmental contamination, captured by taking a photo of the room in standardized conditions
Time frame: Immediately after each procedure (BVM, ETI, LMA)
Provider Workload
Provider workload as measured by NASA TLX survey, rated on a scale of 0-20, with 20 being maximum workload for each element
Time frame: Immediately after each procedure (BVM, ETI, LMA)
Quality of intubation performance
Quality of intubation performance (captured by video review of both video laryngoscopy and video from within the room) assessed using a previously published intubation checklist; rated on a scale of 0 to 41, with 41 being perfect performance
Time frame: Immediately after ETI
Provider opinions on aerosol box
pros and cons of using aerosol box, captured by questionnaire completed by both participants (multiple choice and open field question types)
Time frame: Immediately after all 3 procedures are completed
Plan to share: No — No plan to share data with other researcher. Potential sharing may be possible upon individual request with justification.
No publications or documents are linked to this record.
Ran from Jun 2021 to primary completion in Dec 2021, 6 months.
Of 1,337 non-industry interventional studies with no phase under COVID-19, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's 6 months is below that.
Counting every sponsor, half of 1,475 studies reached it within 9 months; a quarter within 3 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
KidSIM Simulation Program